Cidara Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Cidara Therapeutics, Inc.‘s stocks are currently a part of 40 hedge funds’ portfolios, which represents 57.79% of the total amount of its stocks outstanding. This makes up a total of 30.31M shares of Cidara Therapeutics, Inc.. Compared to the previous quarter, the number fell by -2.51% or -780.92K shares fewer. As for the holding position changes, 30% (12) of current hedge fund investors increased the number of shares held, 25% (10) of current holders sold a part of the shares held, and 40% (16) closed the holdings completely. 5 hedge funds are new holders of Cidara Therapeutics, Inc. stock in Q1 2022, it is 12.5% of total holders.
Hedge funds holding Cidara Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 54 |
|---|---|
| Q3 2017 | 42 |
| Q4 2017 | 48 |
| Q1 2018 | 60 |
| Q2 2018 | 57 |
| Q3 2018 | 60 |
| Q4 2018 | 49 |
| Q1 2019 | 50 |
| Q2 2019 | 44 |
| Q3 2019 | 36 |
| Q4 2019 | 51 |
| Q1 2020 | 51 |
| Q2 2020 | 65 |
| Q3 2020 | 66 |
| Q4 2020 | 63 |
| Q1 2021 | 62 |
| Q2 2021 | 55 |
| Q3 2021 | 49 |
| Q4 2021 | 51 |
| Q1 2022 | 40 |
Hedge funds changes in Cidara Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 22 | 9 | 13 | 20 | -10 |
|---|---|---|---|---|---|
| Q3 2017 | 1 | 14 | 11 | 13 | 3 |
| Q4 2017 | 10 | 16 | 9 | 4 | 9 |
| Q1 2018 | 20 | 15 | 11 | 8 | 6 |
| Q2 2018 | 13 | 18 | 11 | 16 | -1 |
| Q3 2018 | 7 | 19 | 11 | 4 | 19 |
| Q4 2018 | 1 | 14 | 12 | 11 | 11 |
| Q1 2019 | 4 | 8 | 19 | 3 | 16 |
| Q2 2019 | 7 | 8 | 14 | 11 | 4 |
| Q3 2019 | 4 | 9 | 12 | 13 | -2 |
| Q4 2019 | 22 | 7 | 6 | 6 | 10 |
| Q1 2020 | 12 | 30 | 4 | 11 | -6 |
| Q2 2020 | 25 | 21 | 8 | 11 | 0 |
| Q3 2020 | 7 | 24 | 19 | 6 | 10 |
| Q4 2020 | 9 | 22 | 17 | 12 | 3 |
| Q1 2021 | 7 | 22 | 19 | 8 | 6 |
| Q2 2021 | 14 | 10 | 22 | 21 | -12 |
| Q3 2021 | 8 | 12 | 15 | 14 | 0 |
| Q4 2021 | 12 | 19 | 11 | 10 | -1 |
| Q1 2022 | 5 | 12 | 10 | 16 | -3 |
Hedge funds changes in Cidara Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 0 | 0 |
|---|---|---|
| Q3 2017 | 0 | 0 |
| Q4 2017 | 0 | 0 |
| Q1 2018 | 867,000 | 15,000 |
| Q2 2018 | 0 | 0 |
| Q3 2018 | 112,000 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 0 |
| Q3 2019 | 16,000 | 0 |
| Q4 2019 | 18,000 | 0 |
| Q1 2020 | 101,000 | 0 |
| Q2 2020 | 455,000 | 0 |
| Q3 2020 | 154,000 | 58,000 |
| Q4 2020 | 1,000 | 0 |
| Q1 2021 | 7,000 | 0 |
| Q2 2021 | 155,000 | 62,000 |
| Q3 2021 | 162,000 | 0 |
| Q4 2021 | 62,000 | 0 |
| Q1 2022 | 41,000 | 0 |